

Ping An (2318 HK)

1H25 a mixed bag: NBV beat while OPAT in line

Ping An reported mixed 1H25 results, with Group OPAT rising 3.7% YoY to RMB 77.7bn, translating to a 4.9% YoY uptick in 2Q25 (vs.1Q25: +2.4%), in-line with consensus. OPAT of three core business segments (Life, P&C, and PAB) edged up 1% YoY to RMB 76.9bn (98.9% mix), slightly short of our expectations. NBV jumped 39.8% YoY to RMB 22.3bn, a clear beat, mainly driven by bancassurance (+169%, 27% mix). Agency and community finance grew NBV by 17%/43% with margin expansions. In 1H25, the Group's net profit dropped 9% YoY to RMB 68bn with the gap of OPAT (RMB 9.7bn) reflecting 1) RMB4.1bn short-term investment variances for the L&H business; 2) RMB3.4bn one-off losses from the consolidation of Ping An Good Doctor (1833 HK), and 3) RMB2.2bn revaluation losses on the conversion values of USD and HKD convertible bonds issued, given the share price ticking upward. P&C CoR enhanced 2.6pct YoY to 95.2% in 1H25, with auto and non-auto CoR improved by more than 2pct YoY to 95.5%/94.8%. Equity-related investments increased over RMB200bn in 1H25, of which FVOCI stocks took >80% of this increment, making up 65.3% (vs. FY24: 60.2%) of total stocks in insurance funds investment portfolio as of 1H25. To bake in 1H outcome, we revise down our FY25-27E EPS forecasts by 6%/5%/5% to RMB7.08/7.63/8.16, and upgrade FY25E NBV growth estimate to 26%, given potential catalysts of 1) a new round of PIR cut starting in Sep; 2) extensive banca partnerships with large SOEs, reputable joint-stock and city commercial banks, etc; and 3) the Group-wide synergies for client acquisition. We derive our new TP based on SOTP at HK\$71, which corresponds to 0.8x FY25E P/Group EV (vs. trading: 0.6x). Maintain BUY.

■ **Group OPAT largely in line with upticks diverged by lines.** In 1H25, Group OPAT rose 3.7% YoY to RMB77.7bn, with 2Q's growth (+4.9%) outpacing that of 1Q (+2.4%) bolstered by strong rebounds of AM (1H/2Q: +110%/+324%) and Finance enablement business (1H/2Q: +179%/47%). OPAT of three core segments i.e. L&H/P&C/PAB was relatively stable ticking up 1%/1.7% YoY in 1H/2Q25 to RMB76.9bn. L&H OPAT grew 2.5% YoY/flat in 1H/2Q25 to RMB52.4bn, falling short of our expectation. The surge in AM OPAT was mainly driven by 1) Ping An Securities' outperformance amid tailwinds of the A&H stock market boom; 2) a steady rise in AUM of Ping An Asset Management; and 3) unwinding credit risk exposure. Looking ahead, we expect the insurer's L&H OPAT about to reach the inflection point given continued NBV outgrowth and positive operating variances. In 1H25, CSM grew 0.3% from year-start, driven by new business CSM (+6.2%), which contributed 3.3% of CSM release base.

■ **NBV beat driven by bancassurance outgrowth.** NBV jumped 39.8% YoY to RMB 22.3bn, with agency/banca/community finance/group each up by 17%/169%/43%/down 10% YoY to make up 65%/27%/8%/1% of total NBV. Of which, bancassurance was the highlight, with the channel's FYP surging 78% YoY amid a margin expansion of 9.7pct YoY to 28.6% (FYP basis). By cooperating with large SOEs, reputable joint-stock and city commercial banks, we think the banca NBV growth could sustain in the long run, yet may sequentially down in 2H25E. By 1H25, participating NBV comprised >40% mix, which indicated a success of transformation to par policy sales amid a prolonged low-yield environment. With catalysts of the PIR cut starting in Sep, we raise our FY25E NBV growth to 26%.

■ **Valuation:** The stock is trading at FY25E 0.6x P/EV or 0.9x P/B, with a yield of 5.3%. Interim DPS was up 2.2% YoY to RMB 0.95 per share. We revise down our FY25-27E EPS forecasts by 6%/5%/5% to RMB7.08/7.63/8.16 to reflect the lower-than-expected 1H bottom-line results, and roll forward to FY25E forecasts to derive our new TP at HK\$71, corresponding to 0.8x FY25E P/B. Maintain BUY.

Earnings Summary

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Net profit (RMB mn)	115,572	163,433	150,460	156,534	167,384
EPS (Reported)(RMB)	4.84	7.16	7.08	7.63	8.16
Consensus EPS (RMB)	n.a	n.a	7.01	7.68	8.31
P/B (x)	1.0	1.0	0.9	0.8	0.8
P/Embedded value (x)	0.7	0.7	0.6	0.6	0.5
Dividend yield (%)	4.8	5.0	5.3	5.5	5.7
ROE (%)	9.7	13.9	12.5	12.2	12.0

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$71.00
(Previous TP)	HK\$65.10)
Up/Downside	26.1%
Current Price	HK\$56.30

China Insurance

Nika MA

(852) 3900 0805

nikama@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	1,025,223.0
Avg 3 mths t/o (HK\$ mn)	2,726.4
52w High/Low (HK\$)	59.70/34.40
Total Issued Shares (mn)	18210.0

Source: FactSet

Shareholding Structure

Charoen Pokphand Group	13.7%
Company Ltd	
Citigroup Inc.	5.8%


Source: HKEx

Share Performance

	Absolute	Relative
1-mth	3.3%	4.1%
3-mth	21.9%	13.1%
6-mth	16.9%	10.0%

Source: FactSet

12-mth Price Performance



Source: FactSet

Auditor: Ernst & Young

Related reports:

- [1Q25 NBV stayed robust lifting L&H OPAT back to positive growth](#), Apr 28, 2025
- [Life OPAT awaits for longer time to turnaround](#), 24 Mar, 2025
- [Robust 3Q doubled in NBV and earnings growth](#), 23 Oct, 2024
- [2Q NBV stabilized against a high base: expect to see Group OPAT turnaround](#), Aug. 27, 2024
- [Expect \\$3.5bn CB dilutive effect to be short-term](#), Jul. 17, 2024
- [1Q24 NBV beat; Life OPAT y/y turned positive](#), Apr.15, 2024
- [Resilient DPS despite OPAT decline: EV assumptions change cut VNB more than expected](#), Mar 27, 2024

Valuation

(RMB bn, %)	Forward EV/BV	Ownership	Valuation
Life & Health insurance			
FY25E L&H Embedded value	916.5		
Adjusted L&H Embedded value	653.9		
3yr avg. operating RoEV (%)	14.6%		
Target P/EV (x)	1.20x		
L&H, fair value		99.51%	781.8
P&C insurance			
FY25E shareholders' equity	150.1		
3yr avg. P&C ROE (%)	11.6%		
Target P/B (x)	0.91x		
P&C, fair value		99.55%	135.5
Banking			
FY25E shareholders' equity	274.2		
PAB ROE	8.5%		
Target P/B (x)	0.60x		
PAB, fair value		57.96%	94.7
Securities, Trust, and Others AMC			
FY25E shareholders' equity	284.9		
Target P/B (x)	1.00x		
Others, fair value		100.00%	284.9
Sum-of-the-parts total			1,297
Conglomerate discount (%)			-10.0%
Total fair value			1,167
Financial business, price per share (HK\$)			69.7
Tech business, price per share (HK\$)			0.80
Target price (HK\$)			71.0
Implied P/B (x)			1.12x
Implied P/EV (x)			0.78x
Required return	9.5%		
Risk free rate	2.5%		
Risk premiums	7.0%		
Beta	1.4x		
COE	12.5%		
No. of shares outstanding (mn)	18,210		
Stock price, 27/8/2025	56.30		
Upside (%)	26.1%		
Prev. target price	65.1		
Target price chg. (%)	9.1%		

Source: CMBIGM estimates

Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Insurance revenue	525,981	536,440	551,186	565,020	595,150	630,622
Insurance service expenses	(422,221)	(440,178)	(449,102)	(461,379)	(487,147)	(516,823)
Net expenses from reinsurance contracts held	(4,314)	(3,731)	(3,601)	(2,973)	(1,459)	(1,550)
Insurance service results	99,368	92,301	98,127	100,057	105,898	111,567
Net finance (expenses)/income from insurance contracts	(99,933)	(123,959)	(172,662)	(172,836)	(184,229)	(199,612)
Net finance (expenses)/income from reinsurance contracts	564	542	960	163	0	0
Interest income	115,933	118,503	123,627	142,069	158,726	174,028
Net investment income	(2,311)	33,324	161,074	111,024	124,041	135,999
Other gains/(losses) from changes in fair value	(13,300)	(9,940)	(19,814)	5,209	(1,389)	(2,367)
Net investment results	953	18,470	93,185	85,629	97,149	108,048
Net interest income from banking operations	131,096	118,947	93,913	95,056	101,445	104,170
Net interest income/(expenses) from non-banking operations	(22,698)	(24,346)	(19,405)	(21,489)	(22,899)	(24,778)
Loan loss provisions	(64,168)	(62,833)	(56,245)	(65,506)	(68,780)	(68,626)
Other fee and commission income/(expenses)	(9,928)	(8,773)	(7,841)	(7,878)	(7,958)	(7,901)
Other income	60,652	68,804	65,191	73,044	78,432	84,269
Other expenses	(107,779)	(123,515)	(122,417)	(134,058)	(143,017)	(152,510)
Foreign exchange gains/losses	3,144	120	380	842	31	31
Other results	36,301	14,210	(638)	(10,399)	(14,573)	(18,269)
Profit before tax	146,787	126,415	187,195	171,816	185,120	197,944
Income taxes	(7,518)	(10,843)	(23,762)	(21,356)	(28,586)	(30,561)
Net profit	139,269	115,572	163,433	150,460	156,534	167,384
Net profit attributable to shareholders	111,008	85,665	126,607	124,495	134,091	143,418

BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
ASSETS						
Cash and amount due from banks and other financial institutions	774,841	804,077	1,018,027	1,059,860	1,139,897	1,238,621
Balances with central bank and statutory deposits	336,294	329,531	344,608	360,375	424,149	499,209
Intangible assets	99,411	99,078	97,263	98,659	97,877	97,101
Investments in associates and joint ventures	280,793	258,877	185,514	161,147	164,386	167,690
Property	53,657	50,401	48,603	45,587	43,097	40,744
Investment property	114,763	121,406	119,158	126,427	138,436	153,140
Reinsurance contract assets	20,615	22,215	26,084	29,984	33,985	38,323
Loans and advances to customers	3,242,258	3,320,110	3,294,053	3,497,103	3,711,417	4,185,141
Fixed maturity investments	4,729,856	4,976,779	5,912,846	6,503,418	7,161,844	7,967,554
Equity investments	1,073,763	1,130,853	1,328,664	1,562,394	1,690,453	1,847,497
Derivative financial assets	29,278	44,978	68,698	38,498	42,444	46,795
Deferred tax assets	89,321	101,337	122,012	126,607	121,594	116,778
Other assets	165,090	323,775	392,297	940,260	1,550,056	3,098,439
Total assets	11,009,940	11,583,417	12,957,827	14,550,319	16,319,635	19,497,031
LIABILITIES						
Due to banks and other financial institutes	923,088	963,718	838,183	1,199,145	1,259,103	1,322,058
Customer deposits and payables to brokerage customers	3,431,999	3,534,539	3,710,167	3,970,031	4,130,420	4,297,289
Insurance contract liabilities	3,671,177	4,159,801	4,984,795	5,607,870	6,356,040	7,167,384
Obligations under repurchase agreements	271,737	241,803	462,292	539,425	594,716	655,674
Derivative financial instruments	39,738	44,531	74,937	46,521	47,456	48,410
Deferred tax liabilities	14,217	14,148	13,977	8,653	8,319	7,999
Current tax liabilities	16,076	7,117	14,970	33,091	232,472	1,633,143
Other liabilities	1,455,807	1,388,743	1,553,225	1,682,870	2,135,101	2,708,859
Total liabilities	9,823,944	10,354,453	11,653,115	13,087,606	14,763,627	17,840,816
EQUITIES						
Share capital	18,280	18,210	18,210	18,210	18,210	18,210
Reserves	268,724	263,752	221,594	272,975	272,213	271,282
Retained profits	593,183	622,050	693,797	773,390	859,343	952,216
Total shareholders' equity	869,191	899,011	928,600	1,059,574	1,144,765	1,236,707
Non-controlling interests	316,805	329,953	376,112	403,139	411,243	419,509
Total equity	1,185,996	1,228,964	1,304,712	1,462,713	1,556,008	1,656,215
Total liabilities & equity	11,009,940	11,583,417	12,957,827	14,550,319	16,319,635	19,497,031

PER SHARE DATA	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
DPS	2.40	2.48	2.61	2.72	2.83	2.97
EPS (Reported)	8.80	4.84	7.16	7.08	7.63	8.16
Consensus EPS	n.a	n.a	n.a	7.01	7.68	8.31
No. of shares basic	18,280	18,210	18,210	18,210	18,210	18,210
PROFITABILITY	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Return on equity (ROE)	13.2%	9.7%	13.9%	12.5%	12.2%	12.0%
Combined ratio (%)	100.3%	100.7%	98.3%	97.0%	96.7%	96.4%
VALUATION	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
P/Embedded value (x)	0.7	0.7	0.7	0.6	0.6	0.5
P/B (x)	1.1	1.0	1.0	0.9	0.8	0.8
Dividend yield (%)	4.6	4.8	5.0	5.3	5.5	5.7

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets. | Note: stock price data was quoted by market close on Aug 27th, 2025 (Wed).

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.